{"schema_version":"secwatch.filing_event.v1","accession":"0001279569-25-000884","form_type":"8-K","ticker":"CWBHF","cik":"0001750155","company_name":"Charlotte's Web Holdings, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.870707+00:00","generated_at":"2026-05-17T13:57:57.340649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Charlotte's Web Q2 revenue up 4.2% YoY to $12.8M; net loss narrows to $6.3M","bullets":["Revenue $12.8M, +4.2% YoY; net loss $6.3M (-$0.04/share) vs $11.0M loss (-$0.07) in Q2 2024.","Adjusted EBITDA improved 30.8% to -$3.6M; SG&A down 31.7% to $10.1M.","In-house production of Brightside THC gummies expanded; expects ~$9M annualized cost savings by 2026.","Cash $15.3M; working capital $29.4M; reduced cash burn 52% in H1 2025.","DeFloria Phase 2 trials for ASD irritability underway; regulatory progress expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001279569-25-000884","json":"https://secwatch.observer/filing/0001279569-25-000884.json","markdown":"https://secwatch.observer/filing/0001279569-25-000884.md","text":"https://secwatch.observer/filing/0001279569-25-000884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750155/000127956925000884/0001279569-25-000884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750155/000127956925000884/charlotteform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:57.340649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}